Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969300 | 1.00 | POLB (0.52) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL3832124 | 1.00 | POLB (0.52) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL4968512 | 0.94 | AKR1C3 (0.47) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL20590901 | 0.94 | AKR1C3 (0.47) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL1967273 | 0.94 | AKR1C3 (0.47) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL17395384 | 0.92 | AKR1C3 (0.46) | POLBL3MBTL1AKR1C3NAMPTADORA2A | |
| SCHEMBL16965716 | 0.90 | POLB (0.52) | POLBL3MBTL1DPP4ACE | |
| SCHEMBL25423797 | 0.89 | POLB (0.48) | POLBL3MBTL1AKR1C3DPP4HCRTR1 | |
| SCHEMBL5062176 | 0.89 | POLB (0.48) | POLBL3MBTL1AKR1C3DPP4HCRTR1 | |
| SCHEMBL16538428 | 0.89 | POLB (0.48) | POLBL3MBTL1AKR1C3DPP4HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4259637-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116848125-A | H4 antagonist compounds | 赫帕雷斯治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2022233302-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | 上海赛默罗生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3349580-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2014028675-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ENDO PHARMACEUTICALS INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2545046-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| US-20040267010-A1 | Sulfonamide compounds, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1355902-A1 | SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062788-A1 | SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267010-A1 | Sulfonamide compounds, their preparation and use | HTR7, HTR6, SIGMAR1 | POLB 1776/4885L3MBTL1 2854/4885AKR1C3 1536/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885AKR1C3 4217/4885 |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | POLB 3566/4885L3MBTL1 3976/4885AKR1C3 943/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885AKR1C3 4217/4885 |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885AKR1C3 4217/4885 |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GRIN2C, GRIN2A, GRIN2B | POLB 2702/4885L3MBTL1 966/4885AKR1C3 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.